Crispr Therapeutics $CRSP has been in correction mode sine it ran up to almost $74 a share in May. It is now trading just under $40 (10/17), after fading as we anticipated in September when price started to treat the moving average cluster as resistance:Crispr Therapeutics (CRSP) Signals More Correction AheadCRSP Daily Chart(click to enlarge)Short-term Bounce?- CRSP has been in bearish correction, but found buyers at a support area around $35. - If there is a bounce here, I would first anticipate it to be a short-term one, with resistance around $45. - Also, we should watch the RSI. If it bounces up to 60, we should anticipate selling.Deep Correction:- I am anticipating resistance and further correction because of the prevailing hype in 2018. - I wouldn't be surprised if price retreated back near the 2018 lows, around $24-$25. - We can anticipate support here also because it was a previously critical resistance, which might turn into support. - I think CRSP's price development will resemble that of the Gartner Hype Curve:For more perspective, here is the google trends graph of the term "Crispr", which represents the gene-editing technology.Note that the hype has indeed been retreating since peaking in April 2018. Price peaked in June 2018. We are seeing interest wane and questions about implementation in the media (negative press). CRISPR Crashes After Study Highlights Potential Cancer Risk From Gene-Editing (ZeroHedge 6/11/2018)So let's wait for some more downside before trying to jump back into this early-stage, unproven tech. The upside is definitely there, but I will wait for the downside to materialize further before getting back into this risky name.